Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Change in Accured Expenses of $9.1 million for Q2 2026, up 10.29% year-over-year from $8.3 million in Q2 2025, and down 68.12% on a QoQ basis from $28.6 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Change in Accured Expenses for 16 years, with the latest figure at $9.1 million in Q2 2026.
- Change in Accured Expenses for Q2 2026 came in at $9.1 million, up 10.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $970000.0 (up 104.1% YoY), and the FY2025 annual result was -$24.6 million, down 63.61% from the prior year.
- Change in Accured Expenses fell to $9.1 million in Q2 2026, from $28.6 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $42.5 million in Q2 2022 and troughed at -$44.9 million in Q4 2022.
- A 5-year average of -$3.2 million and a median of -$380000.0 in 2023 frame the typical range for Change in Accured Expenses.
- The widest annual swing landed in 2024, when Change in Accured Expenses tumbled 11002.23%; it then surged 626.84% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at -$44.9 million in 2022, then jumped by 99.4% to -$269000.0 in 2023, then tumbled by 11002.23% to -$29.9 million in 2024, then jumped by 98.36% to -$491000.0 in 2025, then soared by 1958.25% to $9.1 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $9.1 million in Q2 2026, $28.6 million in Q1 2026, and -$491000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 9.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.12 Mn |
| Jun 30, 2026 | 9.12 Mn |
| Mar 31, 2026 | 28.62 Mn |
| Mar 31, 2026 | 28.62 Mn |
| Dec 31, 2025 | -40.32 Mn |
| Dec 31, 2025 | -40.32 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Sep 30, 2025 | 3.54 Mn |
| Jun 30, 2025 | 10.78 Mn |
| Jun 30, 2025 | 10.78 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.43 Mn |
| Dec 31, 2024 | -418,000.00 |
| Dec 31, 2024 | -418,000.00 |
| Sep 30, 2024 | -35.44 Mn |
| Sep 30, 2024 | -35.44 Mn |
| Jun 30, 2024 | 10.83 Mn |
| Jun 30, 2024 | 10.83 Mn |
| Mar 31, 2024 | 10.02 Mn |
| Mar 31, 2024 | 10.02 Mn |